Wissenschaft im Labor
Wissenschaft im Labor

Our Science

MorphoSys applies state-of-the-art research capabilities and expertise in novel discovery platforms to develop new compounds.

At MorphoSys, all disciplines and teams work hand in hand to facilitate the advancement of novel compounds, from their discovery through to clinical development.

Value of Science

We believe that successful drug development is not a matter of chance, but based on a profound understanding of disease biology, excellent technologies and extensive experience in the selection, characterization and development of therapeutic candidates.

With our skills, knowlwedge and expertise, we have built a comprehensive portfolio of promising drug candidates. Technologies are an essential part of the development process of a compound. Smarter tools provide faster, more flexible and, ultimately, better-quality access to drug candidates. Our technologies are setting the standard for how antibodies have been made and will be developed in the future. They provide rapid and direct access to fully human antibodies for use as research tools, diagnostics and therapeutics.

Research and Development

Disease areas
Disease areas

Our Search for New Breakthroughs

We are constantly striving to improve our drug development capabilities. Learn more about our main research areas here.

scientist
scientist

Our Technologies

Our focus lies on continuously developing our R&D capabilities to evolve our technologies and accelerate our research and development work around antibodies.

scientist-with-micrsoscope
scientist-with-micrsoscope

Our Pipeline

View our own pipeline and a selection of clinical programs developed by our partners.

MorphoSys’ lighthouse programs

tafasitanab

Tafasitamab

A monoclonal antibody directed against the antigen CD19.

Science

Felzartamab

An anti-CD38 antibody in clinical development to treat autoimmune diseases and multiple myeloma

Pelaresib

Pelabresib

A selective small-molecule designed to promote anti-tumor activity by inhibiting the function of BET proteins

Science

CPI-0209

A second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time